Ab­b­Vie digs in for a long war as Am­gen bags first OK for a Hu­mi­ra biosim­i­lar

The FDA pro­vid­ed its stamp of ap­proval on Am­gen’s biosim­i­lar of Ab­b­Vie’s an­ti-in­flam­ma­to­ry megablock­buster Hu­mi­ra. But don’t look for any cheap­er copies of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.